{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:50:36Z","timestamp":1740178236011,"version":"3.37.3"},"reference-count":29,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advances in treatment have reduced mortality from Hodgkin lymphoma; therefore, greater attention should be focused on minimizing the late effects. A variety of risk-adapted treatment regimens exist that prioritize disease presentation but not patient-specific comorbidities. Herein, we describe a patient with sickle cell disease diagnosed with Hodgkin lymphoma and the considerations made in treatment planning to minimize therapy-related acute toxicity and late effects that overlap with the patient\u2019s preexisting sickle cell disease complications.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008245","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:07:27Z","timestamp":1670004447000},"page":"2042-2046","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Therapy selection for Hodgkin lymphoma in sickle cell disease: balancing risks and benefits"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-4118","authenticated-orcid":false,"given":"Claire E.","family":"Fraley","sequence":"first","affiliation":[{"name":"1Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-435X","authenticated-orcid":false,"given":"Christopher","family":"McKinney","sequence":"additional","affiliation":[{"name":"1Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Nuss","sequence":"additional","affiliation":[{"name":"1Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-3873","authenticated-orcid":false,"given":"Anna R. K.","family":"Franklin","sequence":"additional","affiliation":[{"name":"1Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"2023052315233755800_bib1","unstructured":"National Cancer Institute\n          . National childhood cancer registry: NCCR\u2217explorer: An interactive website for NCCR cancer statistics. Accessed 24 January 2022. https:\/\/nccrexplorer.ccdi.cancer.gov\/."},{"issue":"8","key":"2023052315233755800_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J\u00a0R Soc Med"},{"issue":"13","key":"2023052315233755800_bib3","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2023052315233755800_bib4","first-page":"CD007652","article-title":"Gene therapy for sickle cell disease","author":"Olowoyeye","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023052315233755800_bib5","first-page":"607","volume-title":"AJCC: Cancer Staging Manual","author":"AJCC","year":"2010","edition":"7ed"},{"issue":"23","key":"2023052315233755800_bib6","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-Korholz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"2023052315233755800_bib7","unstructured":"Merck Sharp, Dohme Corp\n          . Safety and efficacy of pembrolizumab (MK-3475) in children and young adults with classical Hodgkin lymphoma (MK-3475-667\/KEYNOTE-667). 2018. ClinicalTrials.gov Identifier: NCT03407144. Accessed 24 January 2022. https:\/\/ClinicalTrials.gov\/show\/NCT03407144. Updated 13 January 2023.."},{"issue":"7","key":"2023052315233755800_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023052315233755800_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023052315233755800_bib10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1378\/chest.10-2133","article-title":"Pulmonary outcomes in survivors of childhood cancer: a systematic review","volume":"140","author":"Huang","year":"2011","journal-title":"Chest"},{"issue":"11","key":"2023052315233755800_bib11","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/cncr.10978","article-title":"Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study","volume":"95","author":"Mertens","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"2023052315233755800_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/ped.2017.0814","article-title":"Acute chest syndrome in children with sickle cell disease","volume":"30","author":"Jain","year":"2017","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"11","key":"2023052315233755800_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1164\/rccm.200601-125OC","article-title":"Abnormal pulmonary function in adults with sickle cell anemia","volume":"173","author":"Klings","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"27","key":"2023052315233755800_bib14","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1200\/JCO.2005.15.107","article-title":"Stroke as a late treatment effect of Hodgkin\u2019s Disease: a report from the Childhood Cancer Survivor Study","volume":"23","author":"Bowers","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"2023052315233755800_bib15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"2023052315233755800_bib16","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2007.14.9088","article-title":"Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"26","author":"Kadan-Lottick","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023052315233755800_bib17","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023052315233755800_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023052315233755800_bib19","first-page":"71","article-title":"Cerebral vasculopathy in sickle cell anemia: diagnostic contribution of positron emission tomography","volume":"93","author":"Powars","year":"1999","journal-title":"Blood"},{"issue":"18","key":"2023052315233755800_bib20","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1097\/MD.0000000000000821","article-title":"Positron emission tomography with 18F-fluorodeoxyglucose in patients with sickle cell acute chest syndrome","volume":"94","author":"de Prost","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2023052315233755800_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1096-8652(199904)60:4<268::AID-AJH3>3.0.CO;2-C","article-title":"Role of positron emission tomography in determining the extent of CNS ischemia in patients with sickle cell disease","volume":"60","author":"Reed","year":"1999","journal-title":"Am J Hematol"},{"issue":"2","key":"2023052315233755800_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.2006.06035.x","article-title":"Positron emission tomography scans for distinguishing between osteomyelitis and infarction in sickle cell disease","volume":"133","author":"Witjes","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2023052315233755800_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/gim.2014.105","article-title":"Adverse events in cancer patients with sickle cell trait or disease: case reports","volume":"17","author":"Swede","year":"2015","journal-title":"Genet Med"},{"issue":"7","key":"2023052315233755800_bib24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/1042819022386833","article-title":"Sickle cell anemia and hematological neoplasias","volume":"43","author":"Paydas","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023052315233755800_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000497480","article-title":"Management of Hodgkin lymphoma in a sickle cell patient: a case report","volume":"12","author":"Ashraf","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"7","key":"2023052315233755800_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/08880010701533637","article-title":"Hodgkin lymphoma in a child with sickle cell anemia","volume":"24","author":"Brown","year":"2007","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"2023052315233755800_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/088800101316921985","article-title":"Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea","volume":"18","author":"Moschovi","year":"2001","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"2023052315233755800_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00277-008-0632-3","article-title":"Hodgkin lymphoma in a sickle cell anaemia child treated with hydroxyurea","volume":"88","author":"Couronne","year":"2009","journal-title":"Ann Hematol"},{"issue":"27","key":"2023052315233755800_bib29","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2042\/2052223\/blooda_adv-2022-008245-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2042\/2052223\/blooda_adv-2022-008245-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:31:21Z","timestamp":1684855881000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/10\/2042\/493409\/Therapy-selection-for-Hodgkin-lymphoma-in-sickle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008245","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}